Sign in
WithdrawnPhase 4

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Key facts

Who runs it
University of Illinois Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 4
Started
1 Jan 2023
Ended
1 Jan 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Imipenem/Cilastatin/Relebactam 1.25g
Record updated
27 November 2024
Why it stopped
Investigator is no longer at University of Illinois

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age ≥18 years of age
  • Admitted to the ICU
  • BMI ≥40 kg/m2 and/or total body weight ≥120 kg
  • Provide a signed and dated written informed consent prior to study participation

Who cannot take part

  • History of seizures and/or receiving 1 or more anti-epileptic agent
  • Actively receiving antimicrobial therapy for treatment of a confirmed or suspected infection
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days prior to the first dose of study medication
  • Has previously participated in this study
  • History of significant hypersensitivity reaction or intolerance to imipenem/cilastatin or carbapenem-based agents (doripenem, ertapenem, or meropenem +/- vaborbactam)
  • Any other condition that may make the patient unsuitable for the study in the judgement of the investigator
  • Serum creatinine ≥1.5 mg/dL
  • Estimated creatinine clearance (CLCR) <60 mL/minute as determined by Cockcroft-Gault equation:
  • Positive serum pregnancy test (for women of childbearing potential)
  • Concomitant use of valproic acid or divalproex sodium
  • Currently breast feeding

Where in United States

  • University of Illinois at ChicagoChicago, United States

About the trial

What the trial wants to find out

This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.

The 2 groups in the trial

  • Pharmacokinetic cohortTreatment being tested

    After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.

    Treatment: Imipenem/Cilastatin/Relebactam 1.25g

  • Safety cohortTreatment being tested

    After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm

    Treatment: Imipenem/Cilastatin/Relebactam 1.25g

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 November 2024